Maxime Dely: How Plasma Exchange Treats Severe Diseases – “A Simple Act Behind a Complex Therapy”
Maxime Dely, Sales and Application Specialist in Therapeutic Apheresis and Cell Therapy, shared a post on LinkedIn:
“Plasma: the invisible therapy that’s already transforming modern medicine!
Plasma exchanges play a crucial role today in treating many severe conditions. Performed using apheresis, they remove harmful components from the patient’s plasma… a highly technical procedure with often remarkable results.
And for this therapy to exist, one key element is essential: albumin.
A protein available exclusively thanks to plasma donations. Without donors, plasma exchanges simply cannot happen.
A major therapeutic tool
Plasma exchanges are used to treat:
• Autoimmune diseases (myasthenia gravis, Guillain-Barré syndrome…)
• Hematological disorders
• Severe neurological conditions
• Kidney diseases
• Complex immunological disorders
This technique removes autoantibodies, toxins or immune complexes that drive the disease.
Looking ahead: incredible new prospects
Recent studies suggest that plasma exchanges may slow the progression of Alzheimer’s disease, opening the door to new approaches for neurodegenerative conditions.
A promising field that could reshape the future of care for millions of patients.
A simple act behind a complex therapy
Plasma exchanges require large amounts of albumin.
Albumin comes only from plasma donors.
Every donation makes these treatments possible.
A heartfelt thank you to all donors: your generosity saves lives every single day.”
Get the latest from Hemostasis Today.
-
Mar 12, 2026, 20:44Honoring Marion Stolte’s Lasting Impact on the Bleeding Disorders Community – WFH
-
Mar 12, 2026, 20:37Paul Riley: Is Thrombin Generation Assay Ready for Prime Time?
-
Mar 12, 2026, 20:28Rob Maloney: Building Visibility for Bleeding Disorders in Rural Georgia
-
Mar 12, 2026, 20:19Akshat Jain: Validating Oral Pain Medication Use as a Global Marker in Sickle Cell Disease
-
Mar 12, 2026, 20:13Michael Makris: Early Clinical Results of AAV8-BDD FVIII Gene Therapy in Hemophilia A
-
Mar 12, 2026, 20:02Wolfgang Miesbach: From Heparin to Vaccines – The Expanding Biology of Anti-PF4 Immunothrombosis
-
Mar 12, 2026, 19:56Christophe Dubois: Celebrating Nicolas Gendron’s HDR Defense and Future in Hemostasis
-
Mar 12, 2026, 17:06Caitlin Raymond: Managing Crigler–Najjar Syndrome Type 1 Crisis Without a Standard TPE Protocol
-
Mar 12, 2026, 17:03Jan Sloves: Insights on Comprehensive Venous Duplex Imaging at VEITH Symposium 2025